This morning! We obtained consent of the pharmaceutical company to provide compassionate drug to metastatic lung cancer patient

Background - A woman in her sixties was diagnosed about two years ago with Small Cell Lung Cancer, SCLC (15% of all lung cancer patients are diagnosed with this type…

Continue ReadingThis morning! We obtained consent of the pharmaceutical company to provide compassionate drug to metastatic lung cancer patient

Recurrent Metastatic Head and Neck Squamous Cell Carcinoma and Salivary Gland Cancer – Two approved drugs demonstrated promising efficacy

Background This phase II trial was designed to evaluate the benefit of Keytruda® plus Zolinza® for recurrent Head and Neck Squamous Cell Carcinoma, HNSCC and Salivary Gland Cancer, SGC. Among…

Continue ReadingRecurrent Metastatic Head and Neck Squamous Cell Carcinoma and Salivary Gland Cancer – Two approved drugs demonstrated promising efficacy

Tremelimumab in Advanced Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

Background Urothelial cancer accounts for 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra. Tremelimumab is an immunotherapy treatment that helps the…

Continue ReadingTremelimumab in Advanced Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

Metastatic colorectal cancer – Tumor location, left or right, impacts efficacy in KRAS/RAS wild-type patients

Background Metastatic colorectal cancer, mCRC, is a group of distinct diseases, with clinical and molecular differences between right-sided and left-sided tumors driving varying prognosis. Patients with KRAS/RAS-wild type (wt) mCRC…

Continue ReadingMetastatic colorectal cancer – Tumor location, left or right, impacts efficacy in KRAS/RAS wild-type patients
Read more about the article HER2 breast cancer patients! 6% complete remission 54.9% shrinkage with Trastuzumab Deruxtecan, DS-8201
girl with leukaemia lying in hospital bed

HER2 breast cancer patients! 6% complete remission 54.9% shrinkage with Trastuzumab Deruxtecan, DS-8201

When was it reported? The outcome of the phase II, multicenter, open-label, single-arm DESTINY-Breast trial was reported at the 2019 San Antonio Breast Cancer Symposium, SABCS, from December 10 –…

Continue ReadingHER2 breast cancer patients! 6% complete remission 54.9% shrinkage with Trastuzumab Deruxtecan, DS-8201